Change in the number of votes relating to Biotie Therapies Corp.'s shares

BIOTIE THERAPIES CORP.         STOCK EXCHANGE RELEASE   2 September 2011 at 11
a.m.
 
Change in the number of votes relating to Biotie Therapies Corp.'s shares
 
The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"),
Biotie Therapies Holding AG (previously Synosia Therapeutics Holding AG) has
conveyed  Biotie shares  Biotie shares against consideration pursuant to the
option programs as follows:
 
August 2011 Total      Options outstanding % of the total amount of shares
            (5-8/2011)
 
89,728      3,495,820  11,214,671          2.9
 
The conveyance of Biotie shares relates to the option plan of Synosia
Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia")
acquired by Biotie in February 2011. According to such Synosia share option
plan, options have been granted to employees, former directors and consultants.
In connection with the completion of the acquisition of Synosia, the option plan
was amended so that instead of shares in Synosia an aggregate maximum of
14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued
these 14,912,155 shares to its current subsidiary Synosia in connection with the
acquisition to be further conveyed to the option holders when they potentially
exercise their option rights in accordance with the terms and conditions of the
option program.
 
The conveyed shares previously held by the Company's subsidiary have not carried
any voting rights.  The parent company Biotie does not own any treasury shares.
The conveyance does not affect the number of registered shares.
 
After the conveyances the changes are as follows:
 
The increase of    A total amount of    The number of the   The total number of
vote of the        voting rights:       Company's share     registered shares
Company                                 held by the Group
August 2011                             August 2011:
 
89,728             376,178,122          11,416,335          387,594,457
 
Turku, 2 September 2011
 
Biotie Therapies Corp.
 
Timo Veromaa
President and CEO
 
For further information, please contact:
 
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com
 
DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: Biotie Therapies Oyj via Thomson Reuters ONE
 
[HUG#1543668]